Inosine pranobex

Oral
Subacute sclerosing panencephalitis
Adult: 50-100 mg/kg daily in divided doses 4 hourly. Max: 3-4 g daily.

Oral
Mucocutaneous herpes simplex
Adult: 1 g 4 times daily for 7-14 days.

Oral
Adjunct in genital warts
Adult: As adjunct to podophyllin or carbon dioxide laser: 1 g tid for 14-28 days.

Hypersensitivity. Gout or elevated uric acid blood levels.

Patient with history of gout or hyperuricaemia, urolithiasis. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor uric acid levels (serum and urine) and renal function, during treatment.

Significant: Increased serum and urine uric acid, acute hypersensitivity reactions (e.g. angioedema, anaphylaxis, urticaria). Gastrointestinal disorders: Constipation, diarrhoea, epigastric discomfort, nausea, vomiting. General disorders and administration site conditions: Fatigue, malaise. Musculoskeletal and connective tissue disorders: Arthralgia. Nervous system disorders: Headache, dizziness, insomnia, nervousness, vertigo. Renal and urinary disorders: Polyuria. Skin and subcutaneous tissue disorders: Rash, pruritus.

Increases the plasma concentration of zidovudine.

Inosine pranobex is a purine derivative with antiviral and immunomodulatory properties. It stimulates T-lymphocyte and macrophage cell function and influences cytokine production, thereby normalising the body's dysfunctional cell-mediated immunity. Synonym: inosine dimepranol acedoben.
Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1 hour.
Metabolism: Rapidly metabolised to uric acid; also undergoes oxidation and glucuronidation.
Excretion: Via urine (as metabolites and unchanged drug). Elimination half-life: 50 minutes.

Oral: Store at or below 30°C.

Antivirals